Generated September 9, 2026 at 8:30 PM ET
· Covers September 9 trading day
· 10 of 177 ready 8-Ks selected
· AI-assisted overview
Today's filings featured a mix of corporate actions and clinical updates. Hallmark Venture Group restated its FY2024-25 financials, citing accounting errors. Independence Realty Trust announced an all-stock acquisition of Centerspace, while Blue Laser Fusion completed a reverse merger with Unite Acquisition. CooperCompanies reported quarterly earnings and expanded its buyback, and both Pyxis Oncology and Tyra Biosciences disclosed positive clinical trial data. Regulatory approvals included a rate increase for American Water and Nasdaq compliance for bioAffinity.
HLLK
HALLMARK VENTURE GROUP, INC.
other material
negative
materiality 1.00
September 9, 2026, 5:06 PM ET
SDR Drone restates FY2024-25 financials; net loss up $2.4M, non-reliance issued
- FY2025 net loss increased $1,569,224; accumulated deficit now $5,315,165 vs $3,745,941 previously.
- FY2024 net loss increased $826,206; accumulated deficit now $3,922,221 vs $3,096,015; restated EPS $(0.56).
- Errors: understated convertible notes payable, misclassified derivative fair value adjustments, revenue recognition, unaccrued expenses.
IRT
INDEPENDENCE REALTY TRUST, INC.
M&A
neutral
materiality 1.00
September 9, 2026, 6:48 AM ET
IRT to acquire Centerspace in all-stock deal at 3.8x exchange ratio; close expected Q4 2026
- IRT to acquire CSR via merger; each CSR share converts to 3.800 IRT shares, cash for fractional shares; close expected Q4 2026.
- IRT OP secured $716M senior unsecured term loan commitment from Royal Bank of Canada to finance deal, assumption/repayment of CSR debt.
- CSR may pay up to $0.77/share quarterly dividend; IRT up to $0.18/share. Termination fees: $45M (CSR) or $60M (IRT).
—
Unite Acquisition 2 Corp.
M&A
neutral
materiality 1.00
September 9, 2026, 6:03 AM ET
Blue Laser Fusion completes reverse merger with Unite Acquisition; raises $25M in PIPE
- Merger closed Sept 4, 2026: Unite Acquisition 2 Corp. merged with Private Blue Laser Fusion; company now Blue Laser Fusion, Inc.
- Private placement of 910,265 units at $27.50/unit raised $25,032,287.50; placement agent warrants for 91,026 shares at $33.00.
- Post-merger: 7,904,099 shares outstanding; 5,993,834 to former Private BLF holders, 910,265 to investors, 1,000,000 to Lucius Partners.
COBA
Chilean Cobalt Corp.
M&A
positive
materiality 0.70
September 9, 2026, 9:03 AM ET
Chilean Cobalt completes Phase 2 at NeoRe rare earth project, advances acquisition, secures $1.5M investment
- Completed Phase 2 earn-in with NeoRe; earned additional 1% NSR, total 2% NSR on NeoRe Rare Earth Project.
- Moving to Phase 3 to negotiate definitive acquisition of 100% of NeoRe for 6,000,000 common shares.
- Madesal SpA invested $1.5M (750k shares at $2.00) as follow-on strategic investment.
INBS
INTELLIGENT BIO SOLUTIONS INC.
regulatory
positive
materiality 0.65
September 9, 2026, 8:50 AM ET
Intelligent Bio Solutions files FDA 510(k) for fingerprint drug screening codeine detection
- Submitted 510(k) to FDA on Sept 9, 2026 seeking clearance for opiate codeine detection via fingerprint sweat analysis.
- Method Comparison Study: accuracy >98%, sensitivity >94%, specificity 100%, verified by LC-MS/MS across 3 U.S. clinical sites.
- Package includes 18 test reports, 170+ attachments, 15,000+ data lines from 18,000+ hours of data collection.
AWK
American Water Works Company, Inc.
regulatory
positive
materiality 0.60
September 9, 2026, 4:19 PM ET
NJBPU approves $68M annual rate increase for American Water's New Jersey subsidiary
- NJBPU approved $68M annualized revenue increase for New Jersey American Water, effective Sept 15, 2026.
- Authorized ROE 9.5%, rate base $6.06B, common equity ratio 54%, long-term debt ratio 46%.
- Increase supports $1.4B in capital investments; includes $9.88 monthly PFAS credit for 12 months.
BIAF
bioAffinity Technologies, Inc.
regulatory
positive
materiality 0.60
September 9, 2026, 8:30 AM ET
bioAffinity regains Nasdaq compliance; hearing cancelled, listing continues
- Regained compliance with Nasdaq Minimum Bid Price Rule 5550(a)(2) and Rights/Warrants Rule 5560(a) as of Sept 8, 2026.
- Previously scheduled Nasdaq Hearings Panel hearing cancelled; BIAF and BIAFW continue trading on Nasdaq Capital Market.
- As of Sept 8, 2026: 1,166,625 shares outstanding; aggregate market value ~$10.4M based on closing price.
COO
COOPER COMPANIES, INC.
earnings
positive
materiality 0.85
September 9, 2026, 4:34 PM ET
CooperCompanies Q3 EPS $2.24 GAAP, $1.15 non-GAAP; completes strategic review, buyback to $3B
- Revenue $1.066B, +1% YoY; GAAP EPS $2.24 (incl. $307.2M tax benefit), non-GAAP EPS $1.15 (+4%).
- Free cash flow $273M, +66% YoY; repurchased $339.1M of stock in Q3.
- Strategic review complete: Board unanimously retains CooperSurgical; buyback authorization raised from $2B to $3B.
PYXS
Pyxis Oncology, Inc.
other material
positive
materiality 0.85
September 9, 2026, 7:34 AM ET
Pyxis Oncology reports 36% cORR, 94% DCR for MICVO in 2L+ HNSCC; Phase 3 planned mid-2027
- MICVO Phase 1 in 2L+ R/M HNSCC: cORR 36% (12/33), DCR 94% (31/33), mPFS 6.2 months, 12-month OS 79%.
- Median OS not reached; 83% of responders had >50% tumor reduction; 75% responded by first scan at 6 weeks.
- No new safety signals; dose capping reduced frequency/severity of AEs in high body weight patients; no treatment-related deaths.
TYRA
Tyra Biosciences, Inc.
other material
positive
materiality 0.85
September 9, 2026, 7:10 AM ET
Tyra reports positive SURF302 data: 79% ORR, 57% CR at 60mg in FGFR3-altered NMIBC
- SURF302: 60mg QD ORR 79% (11/14), CR 57% (8/14) at 3 months; 50mg ORR 67%, CR 33%.
- Safety: no Grade 4/5 TEAEs; Grade 3 treatment-related AEs in 4.5% (2/44), none at 60mg; no dose reductions at 60mg.
- Exposure-response: ORR 86% above AUC 2500 vs 58% below; supports 60mg adjuvant, 70mg cohort planned for ablative.